India’s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday.

The development of HGCO19, the country’s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India’s target of vaccinating all adults by the end of the year as senior government officials have said that — subject to trials and approval — they are looking at availability of 60 million vaccine doses by December.

Leave a Reply

Your email address will not be published. Required fields are marked *

India’s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday.

The development of HGCO19, the country’s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India’s target of vaccinating all adults by the end of the year as senior government officials have said that — subject to trials and approval — they are looking at availability of 60 million vaccine doses by December.

Leave a Reply

Your email address will not be published. Required fields are marked *